PMID- 26497515
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20240329
IS  - 1600-065X (Electronic)
IS  - 0105-2896 (Print)
IS  - 0105-2896 (Linking)
VI  - 268
IP  - 1
DP  - 2015 Nov
TI  - Fcgamma receptor pathways during active and passive immunization.
PG  - 88-103
LID - 10.1111/imr.12343 [doi]
AB  - IgG antibodies are actively produced in response to antigenic challenge or 
      passively administered as an effective form of immunotherapy to confer immunity 
      against foreign antigens. Their protective activity is mediated through their 
      bifunctional nature: a variable Fab domain mediates antigen-binding specificity, 
      whereas the constant Fc domain engages Fcgamma receptors (FcgammaRs) expressed on the 
      surface of leukocytes to mediate effector functions. While traditionally 
      considered the invariant domain of an IgG molecule, the Fc domain displays 
      remarkable structural heterogeneity determined primarily by differences in the 
      amino acid sequence of the various IgG subclasses and by the composition of the 
      complex, Fc-associated biantennary N-linked glycan. These structural determinants 
      regulate the conformational flexibility of the IgG Fc domain and affect its 
      capacity to interact with distinct types of FcgammaRs (type I or type II FcgammaRs). FcgammaR 
      engagement activates diverse downstream immunomodulatory pathways with 
      pleiotropic functional consequences including cytotoxicity and phagocytosis of 
      IgG-coated targets, differentiation and activation of antigen presenting cells, 
      modulation of T-cell activation, plasma cell survival, and regulation of antibody 
      responses. These functions highlight the importance of FcgammaR-mediated pathways in 
      the modulation of adaptive immune responses and suggest a central role for 
      IgG-FcgammaR interactions during active and passive immunization.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bournazos, Stylianos
AU  - Bournazos S
AD  - The Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 
      New York, NY, USA.
FAU - Ravetch, Jeffrey V
AU  - Ravetch JV
AD  - The Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 
      New York, NY, USA.
LA  - eng
GR  - P01 AI100148/AI/NIAID NIH HHS/United States
GR  - R01 CA080757/CA/NCI NIH HHS/United States
GR  - R56 AI034662/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Immunol Rev
JT  - Immunological reviews
JID - 7702118
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/immunology/metabolism
MH  - Humans
MH  - *Immunization, Passive
MH  - Immunoglobulin G/chemistry/classification/*immunology/*metabolism
MH  - Immunomodulation
MH  - Immunotherapy
MH  - Multigene Family
MH  - Protein Binding
MH  - Protein Interaction Domains and Motifs
MH  - Receptors, IgG/chemistry/genetics/*metabolism
MH  - *Signal Transduction
MH  - *Vaccination
PMC - PMC7556827
MID - NIHMS1610670
OTO - NOTNLM
OT  - Fc receptors
OT  - antibodies
OT  - immunotherapies
OT  - inflammation
OT  - vaccination
COIS- The authors have no conflicting financial interests.
EDAT- 2015/10/27 06:00
MHDA- 2016/08/20 06:00
PMCR- 2020/10/14
CRDT- 2015/10/27 06:00
PHST- 2015/10/27 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
PHST- 2020/10/14 00:00 [pmc-release]
AID - 10.1111/imr.12343 [doi]
PST - ppublish
SO  - Immunol Rev. 2015 Nov;268(1):88-103. doi: 10.1111/imr.12343.